EW

Edwards Lifesciences CorpNYSE EW Stock Report

Last reporting period 30 Jun, 2024

Updated 13 Nov, 2024

Last price

Market cap $B

39.957

Large

Exchange

XNYS - New York Stock Exchange, Inc

EW Stock Analysis

EW

Neutral

Based on Eyestock quantitative analysis, EW`s fundamental data and valuation indicate an investment grade of Neutral at the current time.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

90/100

Moderate score

Upside

To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.

56.5 %

Greatly undervalued

Market cap $B

39.957

Dividend yield

Shares outstanding

608.31 B

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient's diseased or defective heart valve. The Company's products and technologies are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care. It also develops hemodynamic and noninvasive brain and tissue oxygenation monitoring systems that are used to measure a patient's cardiovascular function in the hospital setting. The Edwards SAPIEN family of valves, including the Edwards SAPIEN XT, the Edwards SAPIEN 3, and the Edwards SAPIEN 3 Ultra transcatheter aortic heart valves are used to treat heart valve disease. It conducts operations worldwide and is managed in various geographical regions, including the United States, Europe, Japan, and the Rest of the World. It sells products that are used to treat advanced cardiovascular disease in all regions.

View Section: Eyestock Rating